IP Library › Granted Patent US 12,390,658
Granted Patent B2
US 12,390,658 · App. 16/761,078 · Granted Aug 19, 2025

Methods for treating ocular disease

Inventor: Clark E. Tedford (Poulsbo, WA)
Assignee: LumiThera, Inc.
A61N5/0613A61N2005/066A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,658
App. No.
16/761,078
Granted
Aug 19, 2025
Kind
B2
Abstract

Methods for treating ocular diseases such as dry age-related macular degeneration include administering non-invasive photobiomodulation light therapy in the context of a prior PBM treatment, on the basis of a subject response to prior PBM treatment, on the basis of a patient pre-treatment characteristic, and combinations thereof. In some embodiments, methods comprise administering PBM therapy to subjects who have received PBM about four to six months prior to the present administering. In some embodiments, methods comprise administering PBM therapy to subjects in early stages of dry age-related macular degeneration.

Claims (70)

1. A method for treating dry age-related macular degeneration (AMD) in an eye of a subject, comprising:

administering, to the eye of the subject having dry AMD, a first treatment including multiple sessions delivering an effective amount of photobiomodulation (PBM) light comprising one or more of:

(i) light having a wavelength in a yellow range;

(ii) light having a wavelength in a red range; or

(iii) light having a wavelength in a near-infrared (NIR) range;

ceasing administration of the first treatment for a first period having a duration of about 4, 5, or 6 months, wherein the duration of the first period is determined according to a nature, state, severity, or progression of disease or condition of the eye of the subject, or a responsiveness of the subject or disease to the first treatment, or one or more measured characteristics of the eye of the subject that is responsive to the first treatment;

after completion of the first period, administering to the eye of the subject having dry AMD a second treatment including multiple sessions delivering an effective amount of PBM light comprising one or more of:

(i) light having a wavelength in a yellow range;

(ii) light having a wavelength in a red range; or

(iii) light having a wavelength in a near-infrared (NIR) range;

ceasing administration of the second treatment for a second period having a duration of about 4, 5, or 6 months, wherein the duration of the second period is determined according to a nature, state, severity, or progression of disease or condition of the eye of the subject, or a responsiveness of the subject or disease to the second treatment, or one or more measured characteristics of the eye of the subject that is responsive to the second treatment; and

after completion of the second period, administering to the eye of the subject having dry AMD a third treatment including multiple sessions delivering an effective amount of PBM light comprising one or more of:

(i) light having a wavelength in a yellow range;

(ii) light having a wavelength in a red range; or

(iii) light having a wavelength in a near-infrared (NIR) range.

2. The method of claim 1 , wherein, prior to administering the treatment including an effective amount of PBM light, the eye:

(iv) had a best corrected visual acuity (BCVA) score of 70 or more;

(v) had a Snellen BCVA equivalent score of 20/100 or better;

(vi) had an AREDS categorization of AREDS 1, 2 or 3 or 4;

(vii) did not have geographic atrophy (GA) with central fovealor involvement; or

(viii) any combination of (iv)-(vii).

3. The method of claim 1 , wherein administering the treatment including an effective amount of PBM light comprises administering to the eye of the subject two or three of:

(i) the light having a wavelength in the yellow range;

(ii) the light having a wavelength in the red range; or

(iii) the light having a wavelength in the near-infrared (NIR) range.

4. The method of claim 1 , wherein the wavelength in the yellow range is in a range from 550 nm to 620 nm.

5. The method of claim 4 , wherein the wavelength in the yellow range is:

(i) in a range from 560 nm to 610 nm;

(ii) in a range from 570 nm to 600 nm; or

(iii) 590 nm±15 nm.

6. The method of claim 1 , wherein the wavelength in the red range is in a range from 620 nm to 750 nm.

7. The method of claim 6 , wherein the wavelength in the red range is:

(i) in a range from 650 nm to 720 nm; or

11 670±15 nm.

8. The method of claim 1 , wherein the wavelength in the NIR range is in a range from 750 nm to 950 nm.

9. The method of claim 8 , wherein the wavelength in the NIR range is:

(i) in a range from 800 nm to 900 nm;

(ii) in a range from 825 nm to 875 nm; or

(iii) 850 nm±15 nm.

10. The method of claim 1 , wherein administering the treatment including an effective amount of PBM light comprises administering to the eye of the subject two or three of:

(i) light having a wavelength of 590 nm±15 nm;

(ii) light having a wavelength of 670 nm±15 nm; or

(iii) light having a wavelength of 850 nm±15 nm.

11. The method of claim 1 , wherein two or more of the lights are administered to the eye of the subject simultaneously.

12. The method of claim 1 , wherein one or more of the lights is administered to the eye of the subject in a pulsed fashion and one or more of the lights is administered to the eye of the subject in a continuous fashion.

13. The method of claim 1 , wherein one or more of the lights is administered to the eye of the subject while the eye is open and/or wherein one or more of the lights is administered to the eye of the subject while the eye is closed.

14. The method of claim 1 , wherein administering the treatment including an effective amount of PBM light comprises administering to the eye of the subject one or more of:

(i) the light comprising a wavelength in the yellow range for at least 30 seconds;

(ii) the light comprising a wavelength in the red range for at least 75 seconds; or

(iii) the light comprising a wavelength in the near-infrared (NIR) range for at least 30 seconds.

15. The method of claim 1 , wherein the PBM light is administered to the eye at least three or four times in a week.

16. The method of claim 1 , wherein the eye had previously received an effective amount of PBM light about 6 months prior to the administering of the treatment.

17. The method of claim 1 , wherein two or more of the lights are administered to the eye of the subject in a sequence.

18. The method of claim 1 , wherein the treatment includes administering the PBM light to the eye at treatment times in a period of at least three or four weeks.

19. A method for treating dry age-related macular degeneration (AMD) in an eye of a subject, comprising:

administering, to the eye of the subject having dry AMD, a treatment including multiple sessions delivering an effective amount of photobiomodulation (PBM) light comprising one or more of:

(i) light having a wavelength in a yellow range;

(ii) light having a wavelength in a red range; or

(iii) light having a wavelength in a near-infrared (NIR) range;

ceasing administration of the PBM light to the eye of the subject having dry AMD for a period of about 1, 2, or 3 months; and

testing the eye of the subject about 1 month after beginning the treatment including the effective amount of PBM light, and

when the eye of the subject having dry AMD has had an increase in a best corrected visual acuity (BCVA) letter score of less than 5 letters as compared to a BCVA letter score of the eye before receiving the treatment, at about 1 to 3 months after the treatment, administering to the eye of the subject having dry AMD another treatment including multiple sessions delivering an effective amount of PBM light comprising one or more of:

(i) light having a wavelength in a yellow range;

(ii) light having a wavelength in a red range; or

(iii) light having a wavelength in a near-infrared (NIR) range.

20. A method for treating dry age-related macular degeneration (AMD), comprising:

administering photobiomodulation (PBM) treatment to an eye of a subject having dry AMD, wherein the PBM treatment is administered according to a predefined schedule that includes at least three cycles of administering PBM treatment to the eye of the subject, and

wherein each cycle of administering PBM treatment includes:

administering a treatment comprising multiple sessions delivering an effective amount of PBM light comprising one or more of a wavelength in a yellow range, a wavelength in a red range, or a wavelength in a near-infrared (NIR) range; and

ceasing administration of the PBM treatment for a period having a duration of about 4, 5, or 6 months, wherein the duration of the period is determined according to a nature, state, severity, or progression of disease or condition of the eye of the subject, or a responsiveness of the subject or disease to the treatment, or one or more measured characteristics of the eye of the subject that is responsive to the treatment.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2026
From: LUMITHERA, INC.
To: ALCON INC.
Reel/Frame 075931/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: TEDFORD, CLARK E.
To: LUMITHERA, INC.
Reel/Frame 061361/0184 →
Continuity (3)
Provisional Application 62663535 · Apr 27, 2018
Provisional Application 62580972 · Nov 2, 2017
Related Publication 20210178178A1 · Jun 17, 2021
References Cited (46)
US 9062105B1 · Clube · 2015 [cited by applicant]
US 9592404B2 · Dotson et al. · 2017 [cited by applicant]
US 20020183302A1 · Strong · 2002 [cited by examiner]
US 20100150911A1 · Caiado De Castro Neto et al. · 2010 [cited by applicant]
US 20150088231A1 · Rubinfeld et al. · 2015 [cited by applicant]
US 20160067086A1 · Tedford · 2016 [cited by examiner]
US 20160317833A1 · Tedford · 2016 [cited by examiner]
US 20190192345A1 · Gast et al. · 2019 [cited by applicant]
US 20210060354A1 · Eells et al. · 2021 [cited by applicant]
US 20210178178A1 · Tedford · 2021 [cited by applicant]
WO WO2016040534A1 · 2016 [cited by examiner]
Merry, G. F., Munk, M. R., Dotson, R. S. , Walker, M. G. , Devenyl, R. G. (2016). Photobiomodulation reduced drusen volume and improves visual activity and contrast sensitivity in dry-age related macular degeneration. A… [cited by examiner]
“Photobiomodulation for the Treatment of Retinal Diseases: A Review.” International Journal of Ophthalmology, vol. 9, No. 1, 2016, https://doi.org/10.18240/ijo.2016.01.24. (Year: 2016). [cited by examiner]
Scruggs, B. A. (n.d.). Age-related macular degeneration. The University of Iowa. Retrieved Sep. 30, 2022, from https://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/AMD.htm#:˜:text=AMD%20has%20been%20categorized%20by,no%2… [cited by examiner]
Merry, Graham, et al; Treatment of dry Age-related Macular Degeneration using Photobiomodulation; pp. 1-10; 2012. (Year: 2012). [cited by examiner]
Chakravarthy et al., “Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration,” [cited by applicant]
Chew et al., “Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study: AREDS Report No. 36,” [cited by applicant]
Grossman et al., “780 nm Low Power Diode Laser Irradiation Stimulates Proliferation of Keratinocyte Cultures: Involvement of Reactive Oxygen Species,” [cited by applicant]
International Search Report and Written Opinion, mailed Jan. 22, 2019, for International Application No. PCT/US2018/059072. (8 pages). [cited by applicant]
Joachim et al., “The Incidence and Progression of Age-Related Macular Degeneration over 15 Years,” [cited by applicant]
Karu et al., “Irradiation with He—Ne laser increases ATP level in cells cultivated in vitro,” [cited by applicant]
Karu et al., “Cellular Effects of Low Power Laser Therapy Can be Mediated by Nitric Oxide,” [cited by applicant]
Karu et al., “Exact Action Spectra for Cellular Responses Relevant to Phototherapy,” [cited by applicant]
Labrique et al., “A novel device for assessing dark adaptation in field settings,” [cited by applicant]
Nita et al., “The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults,” [cited by applicant]
Sadda et al., “Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3,” [cited by applicant]
Schmitz-Valckenberg et al., “Semiautomated Image Processing Method for Identification and Quantification of Geographic Atrophy in Age-Related Macular Degeneration,” [cited by applicant]
Slakter et al., “Digital Algorithmic Diabetic Retinopathy Severity Scoring System (An American Ophthalmological Society Thesis),” [cited by applicant]
Wong et al., “Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis,” [cited by applicant]
Wong-Riley et al., “Photobiomodulation Directly Benefits Primary Neurons Functionally Inactivated by Toxins,” [cited by applicant]
Wu et al., “Low-Luminance Visual Acuity and Micoperimetry in Age-Related Macular Degeneration,” [cited by applicant]
Yehoshua et al., “Progression of Geographic Atrophy in Age-Related Macular Degeneration Imaged with Spectral Domain Optical Coherence Tomography,” [cited by applicant]
Zhao et al., “Age-Related Retinopathy in NRF2-Deficient Mice,” [cited by applicant]
Friberg et al., “Is Drusen Area Really So Important? An Assessment of Risk of Conversion to Neovascular AMD Based on Computerized Measurements of Drusen,” [cited by applicant]
Ishikawa, “Abnormalities in Glutamate Metabolism and Excitotoxicity in the Retinal Diseases,” [cited by applicant]
Tang et al., “Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema,” [cited by applicant]
Tang, J. et al., “Low-Intensity Far-Red Light Inhibits Early Lesions That Contribute to Diabetic Retinopathy: In Vivo and In Vitro”, IOVS, vol. 54, No. 5, May 2013, 10 pages. [cited by applicant]
Cheng, Y. et al., “Photobiomodulation Inhibits Long-term Structural and Functional Lesions of Diabetic Retinopathy”, Diabetes, vol. 67, Feb. 2018, 8 pages. [cited by applicant]
Saliba, A. et al., “Photobiomodulation Mitigates Diabetes-Induced Retinopathy by Direct and Indirect Mechanisms: Evidence from Intervention Studies in Pigmented Mice”, PLOS One 10(10), Oct. 1, 2015, 14 pages. [cited by applicant]
Eells et al., “Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy,” [cited by applicant]
Light Bioscience, “Gentlewaves LED Photomodulation Device,” downloaded from http://www.lightbioscience.com/led_device.html on Mar. 1, 2005, 1 page. [cited by applicant]
LumiThera, “Photobiomodulation for eye diseases,” Selected Abstracts, Aug. 21, 2013. (24 pages). [cited by applicant]
Riverside Facial Plastic Surgery and Sinus Center, “Gentlewaves LED Photomodulation Fact Sheet,” downloaded from http://www.riversideface.com/pages/gentlewaves.html on Mar. 9, 2015, 4 pages. [cited by applicant]
Tosk, “FDA Clears GentleWaves: The First and Only Light Emitting Diode Device for the Treatment of Periorbital Wrinkles and Rhytids,” downloaded from http://www.drmcdaniel.com/fda-clears-gentlewaves on Mar. 9, 2015, 2 p… [cited by applicant]
Bearse Jr. et al., “A multifocal electroretinogram model predicting the development of diabetic retinopathy”, ScienceDirect, Progress in Retinal and Eye Research 25, 2006, 425-448. [cited by applicant]
Kauppinen et al., “Inflammation and its role in age-related macular degeneration”, Cell Mol Life Sci. 2016, 73(9):1765-1786, 22 pages. [cited by applicant]
Cited By (1)
US 12,708,259